Carcinoma clinical trials at UC Health
1 in progress, 1 open to new patients

Study of LOXO-101 (Larotrectinib) in Subjects With NTRK Fusion Positive Solid Tumors (NAVIGATE)

open to eligible people ages 12 years and up

Phase II, multi-center, open-label study of patients with advanced solid tumors harboring a fusion of NTRK1, NTRK2 or NTRK3.

at UCLA